Wednesday, October 25, 2023 9:19:40 AM
The way this has worked in the past on the Bio Tech stocks I have had is they get preliminary results then they have to clean them up by checking to ensure the results are not tainted by test results being reported wrong... and then if they like what they have they begin prepping what is needed to submit the information to the FDA... FDA will make a determination if there is more information needed or if they needed to expand something in the testing, if the FDA likes all that has been submitted and the results are all sufficient safety wise and results wise, they can begin the process of commercializing the product.
Recent JAGX News
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:50 PM
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs • ACCESS Newswire • 04/08/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:22 PM
- Jaguar Health Reports 2025 Financials • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/07/2026 10:10:28 AM
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress • ACCESS Newswire • 04/02/2026 01:00:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:19:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 09:06:18 PM
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 03/18/2026 01:00:00 PM
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression • ACCESS Newswire • 03/16/2026 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/13/2026 08:59:50 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts • ACCESS Newswire • 03/11/2026 01:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:05:16 PM
- Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants • ACCESS Newswire • 03/09/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 02:05:51 PM
- Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 • ACCESS Newswire • 03/03/2026 02:00:00 PM
- Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend • ACCESS Newswire • 03/02/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:01:37 PM
- Jaguar Health Announces a Special One-time Stock Dividend • ACCESS Newswire • 02/18/2026 02:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:12:24 PM

